Researchers today have a many choices when deciding which sequencing technology to use for their clinical research. Sanger sequencing, long the “gold standard” in clinical research sequencing technology, has met significant competition with the advent of next generation sequencing (NGS). NGS technologies are now commonplace in clinical research laboratories where they have enabled rapid advances in the gathering and analysis of genetic information. However, with these advances have come additional challenges involving validation as these technologies become more widespread and move closer to future clinical application. In this webinar, our expert speakers will discuss the relative benefits of Sanger and NGS technologies and their application in different fields of clinical research.
During the webinar, the speakers will:
• Compare and contrast Sanger sequencing and NGS approaches
• Describe the most relevant applications for both Sanger sequencing and NGS
• Discuss future clinical research applications of both Sanger sequencing and NGS
• Answer your questions live!
Miguel E. Quiñones-Mateu, Ph.D.
Dr. Quiñones-Mateu's successful career encompasses over 20 years of productive research in HIV/AIDS in three different countries. He holds a Bachelor's degree in biology from the Universidad Central de Venezuela and completed his Ph.D. in molecular biology at the Centro de Biologia Molecular "Severo Ochoa," Universidad Autónoma de Madrid, Spain. He continued his training as a postdoctoral fellow in the Department of Medicine at Case Western Reserve University, prior to becoming an assistant professor in the Department of Virology, The Cleveland Clinic. Recently, and following a five-year hiatus in the corporate world (Diagnostic Hybrids, a Quidel Company), Dr. Quiñones-Mateu returned to the academia as assistant professor of pathology at CWRU and scientific director of the University Hospital Translational Laboratory (www.uhtl.org). He is also co-director of the Virology and Next Generation Sequencing Core in the Center for AIDS Research at Case Western Reserve University. His current work focuses on understanding the mechanisms and clinical consequences of drug resistant viruses, including transmission and pathogenicity studies, using next generation sequencing technology.
Volker Endris, Ph.D.
Dr. Endris studied biology at the Saarland University in Saarbrücken, Germany and completed his undergraduate training in the Department of Human Genetics at the Saarland Medical University. He then moved to the Department of Human Genetics at Heidelberg University, where he completed his Ph.D. in 2004 working on the genetic causes of intellectual disabilities. Dr. Endris continued his work in the Heidelberg Human Genetics Department as a postdoctoral researcher. Since 2012, he has worked as a research associate at the Department of Pathology at Heidelberg Medical Hospital, heading the next generation sequencing facility section. His current work focuses on the implementation of amplicon-based next generation sequencing for the routine molecular diagnostics of formalin-fixed, paraffin-embedded tumor material.
Moderator: Sean Sanders, Ph.D.
Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Editor for Custom Publishing for the journal Science and Program Director for Outreach.
For product or technologies related to this webinar, go to: http://www.lifetechnologies.com/targeteddna